Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer

ClinicalTrials.gov ID: NCT07816666

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07816666. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan With or Without Bevacizumab Versus Standard of Care as Second- or Third-Line Maintenance Treatment in Participants With Platinum-sensitive Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (TREVI-OC-03)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive relapsed ovarian cancer (PSR OC)

Study identification

NCT ID: NCT07816666
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: AstraZeneca; Industry
Enrollment: 600 participants

Conditions and interventions

Conditions

Interventions

Torvutatug samrotecan Drug
Bevacizumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 24, 2026 (Actual)
Primary completion: Sep 29, 2028 (Estimated)
Completion: Oct 30, 2031 (Estimated)
Last update posted: Oct 16, 2026

2026 – 2031

United States locations

U.S. sites: 26
U.S. states: 14
U.S. cities: 24

Facility	City	State	ZIP	Site status
Research Site	Anchorage	Alaska	99508	Not yet recruiting
Research Site	Miami	Florida	33133	Not yet recruiting
Research Site	Indianapolis	Indiana	46260	Not yet recruiting
Research Site	Shreveport	Louisiana	71103	Not yet recruiting
Research Site	Columbia	Maryland	21044	Not yet recruiting
Research Site	Ann Arbor	Michigan	48109	Not yet recruiting
Research Site	Detroit	Michigan	48201	Not yet recruiting
Research Site	Albany	New York	12206	Not yet recruiting
Research Site	Bay Shore	New York	11706	Withdrawn
Research Site	Buffalo	New York	14263	Not yet recruiting
Research Site	Greenlawn	New York	11740	Withdrawn
Research Site	New Hyde Park	New York	11042	Withdrawn
Research Site	New York	New York	10011	Not yet recruiting
Research Site	New York	New York	10029	Not yet recruiting
Research Site	Rego Park	New York	11374	Withdrawn
Research Site	Cleveland	Ohio	44111	Not yet recruiting
Research Site	Cleveland	Ohio	44195	Not yet recruiting
Research Site	Columbus	Ohio	43210	Withdrawn
Research Site	Mayfield Heights	Ohio	44124	Not yet recruiting
Research Site	Oklahoma City	Oklahoma	73104	Withdrawn
Research Site	Philadelphia	Pennsylvania	19107	Not yet recruiting
Research Site	Willow Grove	Pennsylvania	19090	Not yet recruiting
Research Site	Houston	Texas	77030	Not yet recruiting
Research Site	Salt Lake City	Utah	84112	Not yet recruiting
Research Site	Norfolk	Virginia	23502	Not yet recruiting
Research Site	Morgantown	West Virginia	26506	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 97 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07816666, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 16, 2026 · Synced Nov 15, 2026